References
1. Ngai L.L., Kelder A., Janssen J., Ossenkoppele G.J., Cloos J. MRD Tailored Therapy in AML: What We Have Learned So Far. Front Oncol. 2020; 10: 603636. DOI: https://doi.org/10.3389/fonc.2020.603636
2. Demaria O., Cornen S., Daeron M., Morel Y., Medzhitov R., Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019; 574 (7776): 45–56. DOI: https://doi.org/10.1038/s41586-019-1593-5
3. Chiossone L., Dumas P.Y., Vienne M., Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018; 18 (11): 671–88. DOI: https://doi.org/10.1038/s41577-018-0061-z
4. Zabotina T.N., Chertkova, A.I., Kadagidze, Z.G., Borunova, A.A., Shoua, E.K., Gordeeva, O.O., Meshcheryakov, A.A. Peripheral blood CD8+-lymphocytes populations and its value for direct and outlying treatment results in triple negative breast cancer patients. Immunologiya. 2021; 41 (4): 326–36. DOI: https://doi.org/10.33029/0206-4952-2020-41-3-326-336
5. Galluzzi L., Buque A., Kepp O., Zitvogel L., Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015; 28 (6): 690–714. DOI: https://doi.org/10.1016/j.ccell.2015.10.012
6. Aldarouish M., Su X., Qiao J., Gao C., Chen Y., Dai A., et al. Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer. Int J Immunopathol Pharmacol. 2019; 33: 2058738419839592. DOI: https://doi.org/10.1177/2058738419839592
7. Estey E.H. Acute myeloid leukemia: 2021 update on risk-stratification and management. Am J Hematol. 2020; 95 (11): 1368–98. DOI: https://doi.org/10.1002/ajh.25975
8. Murabito A., Hirsch E., Ghigo A. Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer? Front Cardiovasc Med. 2020; 7: 35. DOI: https://doi.org/10.3389/fcvm.2020.00035
9. Grinko E.K., Donetskova, A.D., Mukhina, E.A., Andreeva, O.S., Sharova, N.I., Komogorova, V.V., Litvina, M.M., Marzanova, S.N., Mitin, A.N. Dynamics of T-lymphocytes regeneration after lymphopenia induction by cyclophosphane. Immunologiya. 2021; 41 (4): 285–94. DOI: https://doi.org/10.33029/0206-4952-2020-41-4-285-294
10. Wijayahadi N., Haron M.R., Stanslas J., Yusuf Z. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. J Chemother. 2007; 19 (6): 716–23. DOI: https://doi.org/10.1179/joc.2007.19.6.716
11. Waidhauser J., Schuh A., Trepel M., Schmalter A.K., Rank A. Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer. Cancer Immunol Immunother. 2020; 69 (1): 147–57. DOI: https://doi.org/10.1007/s00262-019-02449-y
12. Hansen B.A., Wendelbo O., Bruserud O., Hemsing A.L., Mosevoll K.A., Reikvam H. Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment. Mediterr J Hematol Infect Dis. 2020; 12 (1): e2020009. DOI: https://doi.org/10.4084/MJHID.2020.009
13. Opzoomer J.W., Sosnowska D., Anstee J.E., Spicer J.F., Arnold J.N. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. Front Immunol. 2019; 10: 1654. DOI: https://doi.org/10.3389/fimmu.2019.01654
14. Romero A.I., Chaput N., Poirier-Colame V., Rusakiewicz S., Jacquelot N., Chaba K., et al. Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Ralpha and NKG2D triggering. Cancer Res. 2014; 74 (1): 68–80. DOI: https://doi.org/10.1158/0008-5472.CAN-13-1186
15. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010; 70 (8): 3052–61. DOI: https://doi.org/10.1158/0008-5472.CAN-09-3690
16. Kim J.E., Jang M.J., Lee J.I., Chung Y.H., Jeong J.H., Hung C.F., et al. Cancer cells containing nanoscale chemotherapeutic drugs generate antiovarian cancer-specific CD4+ T cells in peritoneal space. J Immunother. 2012; 35 (1): 1–13. DOI: https://doi.org/10.1097/CJI.0b013e3182328569
17. Cao G., Wang J., Zheng X., Wei H., Tian Z., Sun R. Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6. J Biol Chem. 2015; 290 (50): 29964–73. DOI: https://doi.org/10.1074/jbc.M115.674010
18. Toffoli E.C., Sheikhi A., Hoppner Y.D., de Kok P., Yazdanpanah-Samani M., Spanholtz J., et al. Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers (Basel). 2021; 13 (4). DOI: https://doi.org/10.3390/cancers13040711
19. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007; 56 (5): 641–8. DOI: https://doi.org/10.1007/s00262-006-0225-8
20. Obiedat A., Charpak-Amikam Y., Tai-Schmiedel J., Seidel E., Mahameed M., Avril T., et al. The integrated stress response promotes B7H6 expression. J Mol Med (Berl). 2020; 98 (1): 135–48. DOI: https://doi.org/10.1007/s00109-019-01859-w
21. Lee H.G., Baek H.J., Kim H.S., Park S.M., Hwang T.J., Kook H. Biphenotypic acute leukemia or acute leukemia of ambiguous lineage in childhood: clinical characteristics and outcome. Blood Res. 2019; 54 (1): 63–73. DOI: https://doi.org/10.5045/br.2019.54.1.63
22. Clark P., Normansell D.E., Innes D.J., Hess C.E. Lymphocyte subsets in normal bone marrow. Blood. 1986; 67 (6): 1600–6.
23. Buckley S.A., Othus M., Vainstein V., Abkowitz J.L., Estey E.H., Walter R.B. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Am J Hematol. 2014; 89 (4): 423–8. DOI: https://doi.org/10.1002/ajh.23661
24. Dohner H., Estey E., Grimwade D., Amadori S., Appelbaum F.R., Buchner T., et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129 (4): 424–47. DOI: https://doi.org/10.1182/blood-2016-08-733196
25. McBride J.A., Striker R. Imbalance in the game of T cells: What can the CD4/CD8 T-cell ratio tell us about HIV and health? PLoS Pathog. 2017; 13 (11): e1006624. DOI: https://doi.org/10.1371/journal.ppat.1006624
26. Sigel K., Wisnivesky J., Crothers K., Gordon K., Brown S.T., Rimland D., et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. Lancet HIV. 2017; 4 (2): e67–e73. DOI: https://doi.org/10.1016/S2352-3018(16)30215-6
27. Tancini G., Barni S., Rescaldani R., Fiorelli G., Vivani S., Lissoni P. Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. Oncology. 1990; 47 (5): 381–4. DOI: https://doi.org/10.1159/000226852
28. Wahlin B.E., Sander B., Christensson B., Ostenstad B., Holte H., Brown P.D., et al. Entourage: the immune microenvironment following follicular lymphoma. Blood Cancer J. 2012; 2 (1): e52. DOI: https://doi.org/10.1038/bcj.2011.53
29. Kelly-Rogers J., Madrigal-Estebas L., O'Connor T., Doherty D.G. Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol. 2006; 67 (11): 863–73. DOI: https://doi.org/10.1016/j.humimm.2006.08.292
30. Van Acker H.H., Capsomidis A., Smits E.L., Van Tendeloo V.F. CD56 in the Immune System: More Than a Marker for Cytotoxicity? Front Immunol. 2017; 8: 892. DOI: https://doi.org/10.3389/fimmu.2017.00892
31. Knaus H.A., Berglund S., Hackl H., Blackford A.L., Zeidner J.F., Montiel-Esparza R., et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018; 3 (21). DOI: https://doi.org/10.1172/jci.insight.120974
32. Poli A., Michel T., Theresine M., Andres E., Hentges F., Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009; 126 (4): 458–65. DOI: https://doi.org/10.1111/j.1365-2567.2008.03027.x
33. Campbell K.S., Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013; 132 (3): 536–44. DOI: https://doi.org/10.1016/j.jaci.2013.07.006
34. Rey J., Fauriat C., Kochbati E., Orlanducci F., Charbonnier A., D'Incan E., et al. Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells. Front Immunol. 2017; 8: 64. DOI: https://doi.org/10.3389/fimmu.2017.00064
35. Hatjiharissi E., Xu L., Santos D.D., Hunter Z.R., Ciccarelli B.T., Verselis S., et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007; 110 (7): 2561–4. DOI: https://doi.org/10.1182/blood-2007-01-070656
36. Wang W., Erbe A.K., Hank J.A., Morris Z.S., Sondel P.M. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol. 2015; 6: 368. DOI: https://doi.org/10.3389/fimmu.2015.00368
37. Kared H., Martelli S., Ng T.P., Pender S.L., Larbi A. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother. 2016; 65 (4): 441–52. DOI: https://doi.org/10.1007/s00262-016-1803-z
38. MacFarlane A.W.t., Jillab M., Smith M.R., Alpaugh R.K., Cole M.E., Litwin S., et al. NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology. 2017; 6 (7): e1330235. DOI: https://doi.org/10.1080/2162402X.2017.1330235